QUIA PHARMA AB (FRA:99B0) Total Stockholders Equity: €0.59 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is QUIA PHARMA AB Total Stockholders Equity?

QUIA PHARMA AB FRA:99B0 Total Stockholders Equity is €0.59 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

QUIA PHARMA AB's Total Stockholders Equity for the quarter that ended in Jun. 2025 was €0.59 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. QUIA PHARMA AB's Book Value per Share for the quarter that ended in Jun. 2025 was €0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. QUIA PHARMA AB's Debt-to-Equity for the quarter that ended in Jun. 2025 was 0.00.


QUIA PHARMA AB  (FRA:99B0) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

QUIA PHARMA AB's Book Value per Share for the quarter that ended in Jun. 2025 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

QUIA PHARMA AB's Debt-to-Equity for the quarter that ended in Jun. 2025 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


QUIA PHARMA AB Total Stockholders Equity Related Terms


QUIA PHARMA AB Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for QUIA PHARMA AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

QUIA PHARMA AB Total Stockholders Equity Chart

QUIA PHARMA AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.00 0.22 1.36 1.04

QUIA PHARMA AB Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 1.36 3.07 1.04 0.59
What does a Total Stockholders Equity of €0.59 Mil mean?
QUIA PHARMA AB (FRA:99B0) has a Total Stockholders Equity of €0.59 Mil as of Jun. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for QUIA PHARMA AB and its competitors.
Is QUIA PHARMA AB's Total Stockholders Equity too high?
QUIA PHARMA AB's current Total Stockholders Equity is €0.59 Mil.
How does QUIA PHARMA AB's Total Stockholders Equity compare to VRTX and REGN?
QUIA PHARMA AB's Total Stockholders Equity of €0.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for QUIA PHARMA AB and its competitors. QUIA PHARMA AB's current Total Stockholders Equity is €0.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QUIA PHARMA AB stock overvalued right now?
QUIA PHARMA AB (FRA:99B0) has a current Total Stockholders Equity of €0.59 Mil. The current Total Stockholders Equity is €0.59 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For QUIA PHARMA AB (FRA:99B0), the current Total Stockholders Equity is €0.59 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

QUIA PHARMA AB Business Description

Address Virdings Alle 32 B, Uppsala, SWE, 754 50
QUIA PHARMA AB is a development company for pharmaceuticals based on a patented drug delivery platform, Uni-Qleaver. The company develops improved and patentable forms of drugs under development or already approved by pharmaceutical authorities. These refined and enhanced forms of medicine are based on the Company's exceptional and patented technology platform. In addition to this, the Company offers multinational sales of omega-3, astaxin and collagen through Amazon.